TY  - CHAP
M1  - Book, Section
TI  - Antibody-Mediated Coagulation Factor Deficiencies
A1  - Stowell, Sean R.
A1  - (Pete) Lollar, John S.
A1  - Meeks, Shannon L.
A2  - Kaushansky, Kenneth
A2  - Levi, Marcel
PY  - 2017
T2  - Williams Hematology Hemostasis and Thrombosis
AB  - SUMMARYClinically  significant  autoantibodies  to  coagulation  factor  deficiencies  are  uncommon  but  can  produce  life-threatening  bleeding  and  death.  The  most  commonly  targeted  coagulation  factor  in  autoimmunity  is  factor  VIII.  Acquired  hemophilia  A,  which  results  from  these  antibodies,  can  either  be  idiopathic  or  associated  with  older  age,  other  autoimmune  disorders,  malignancy,  the  postpartum  period,  or  the  use  of  drugs  such  as  penicillin  and  sulfonamides.  Bleeding  in  acquired  hemophilia  A  is  treated  with  factor  VIII–bypassing  agents.  The  underlying  autoimmune  disorder  frequently  responds  to  immunosuppressive  medication.  Antiprothrombin  antibodies  usually  are  found  in  patients  with  lupus  anticoagulant  and  are  associated  with  bleeding.  Antibodies  of  von  Willebrand  factor  are  found  in  patients  with  type  3  von  Willebrand  disease  in  response  to  infusion  of  plasma  concentrates  containing  von  Willebrand  factor.  Antibodies  to  factor  V  can  occur  as  autoantibodies  or  as  cross-reacting  antibovine  factor  V  antibodies  that  develop  after  exposure  to  bovine  thrombin  products  that  are  contaminated  with  factor  V.  Pathogenic  autoantibodies  also  have  been  described  that  target  thrombin,  factor  IX,  factor  XI,  factor  XIII,  protein  C,  protein  S,  and  the  endothelial  cell  protein  C  receptor.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/19
UR  - accesscardiology.mhmedical.com/content.aspx?aid=1148373072
ER  -